{"database": "openregs", "table": "dockets", "rows": [["FDA-2022-P-0558", "FDA", "Requests that the FDA to determine if the Reference Listed Drug (RLD), OXANDRIN (oxandrolone tablets, USP) 2.5 mg and 10 mg, NDA 013718 owned by Gemini Laboratories LLC was voluntarily withdrawn from sale for reasons of safety or effectiveness to facilitate the approval of generic version.", "Nonrulemaking", "2026-10-07T14:02:12Z", "0b00006485000253", null, null, null, null, null, null, null, null, null, null, "list_pull"]], "columns": ["id", "agency_id", "title", "docket_type", "last_modified", "object_id", "rin", "dkabstract", "category", "subtype", "keywords", "program", "short_title", "effective_date", "organization", "attrs_raw", "attr_source"], "primary_keys": ["id"], "primary_key_values": ["FDA-2022-P-0558"], "units": {}, "query_ms": 0.22830814123153687, "source": "U.S. government sources, plus a few identifier registries; each is listed on the methodology page", "source_url": "https://datadawn.org/methodology#data", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}